Reports Pfizer is considering buying Allergan to create a company worth $330bn have once again raised fears of disruption for contract research organisations (CRO), although there are reasons to think the deal would be less troublesome than earlier megamergers.
The Coalition for Clinical Trials Awareness (CCTA) has called for a federally-supported public health campaign to make people more aware of drug research and the value of participating in studies.
Pollution caused by pharmaceuticals in wastewater is a major challenge facing the industry, but researchers in Greece may have come up with a solution.
A team of researchers has modified a lectin protein found in bananas to diminish its inflammatory properties, potentially setting it on the path to use as an antiviral.
Covance has reported capacity use at its preclinical toxicology business is in the 70% range, meaning it is still well below optimal levels despite recent improvements.
CRO SNBL USA, daughter company of Shin Nippon, has won a BARDA contract for animal models to treat injuries from chemical, radiological and nuclear attack.
Irish scientists have completed the most comprehensive structural study yet of a PEGylated protein, giving greater insight into how such molecules improve injectable therapies.
A GlaxoSmithKline plant in China that was hit by an explosion in the summer has had its Good Manufacturing Practice (GMP) certificate revoked by the UK medicines regulator.
The number of clinical trials given the green light in Russia has increased 13% in the third quarter of the year, which could be thanks in part to a reduction in red tape.
Science 37 has raised $6.5m (€5.7m) from Lux Capital and dRx Capital, the fund set up by Novartis and Qualcomm, to advance its virtual clinical trial service business.
A nanoparticle that binds to immune cells in the body has been shown to tune down inflammation and offer a potential first-of-a-kind treatment for sepsis.
Quintiles has formed an alliance with information and technology provider IMS Health to access real-world drug data to be used in post-approval clinical research.
Around 500,000 doses of unlicensed erectile dysfunction (ED) drugs have been seized by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).
As pharma sells off manufacturing capacity and outsources to large and specialist CMOs, smart contract houses will have an opportunity to grab market share in a currently fragmented sector, say experts.
An expanded San Diego facility will support demand for preclinical and clinical development services driven by the growth in the antibody and biosimilar sector, Intertek says.
An advisor to the pharma industry on M&A says the current boom in pharma valuations will not last, and R&D cost pressures will reshape firms of the future.
Syngene says it will invest in new capacity and capabilities, including a viral testing facility, as it reports strong results in its first quarter post-IPO.
Piramal chief executive Vivek Sharma won last week’s CPhI award for the pharma industry’s CEO of the year. Outsourcing-Pharma.com spoke to Sharma about his plans for the CDMO the day after the jury’s unanimous decision.
EMD Millipore will offer drugmakers two-years of unlimited access to its suite of raw materials dossiers for 20,000€ as part of its enhanced portfolio offering.
Pharma is looking to condense the number of contract manufacturers it works with, says Aesica which has launched a service to help manage its customers’ supply chain.
Quintiles and Covance are best placed to benefit from the increasing trend of leveraging existing data to increase trial efficiency, according to an analyst survey.
CDMO Ajinomoto Althea is opening a new facility to offer outsourced ADC (antibody drug conjugate) and HPAPI (highly potent active pharmaceutical ingredient) manufacturing, the Californian company has announced.
Big Pharma has returned to Europe for its API sourcing due to reasons of quality and reliability, according to the European Fine Chemicals Group (EFCG).
API suppliers should be allowed to make process improvements without having to seek re-approval says consultant Girish Malhotra, who argues that the current rules create inefficiency and waste.
Rival injectable drug contractors were felled by a stricter MHRA take on rules says Symbiosis' CEO who is confident his firm's compliance record will help it thrive.
Catalent says it is contemplating expanding its Wisconsin single-use biologics facility as strong demand from SMEs and biotechs has almost filled current capacity.
DSM may have narrowed the focus of its pharmaceutical business in recent years, but the Netherlands-based supplier is still trying to win drug industry customers at a trade show in Spain.
